---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018697"
form_type: "8-K"
ticker: "BMRA"
cik: "0000073290"
company_name: "BIOMERICA INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:24:50.621088+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biomerica receives Nasdaq bid price deficiency notice; enters $5.5M at-market stock offering

## Summary
- Nasdaq notified Biomerica on May 7, 2024 that bid price was below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).
- Company has 180 days (until Nov 4, 2024) to regain compliance; 10 consecutive days at $1.00+ required.
- Entered At Market Issuance Sales Agreement with EF Hutton and R.F. Lafferty on May 10, 2024 to sell up to $5.5M of common stock.
- Proceeds for general corporate purposes including sales/marketing, clinical studies, product development, acquisitions, and working capital.
- Sales Agents receive 2.0% commission per share sold.

## SEC filing metadata
- accession: 0001493152-24-018697
- form_type: 8-K
- ticker: BMRA
- cik: 0000073290
- company_name: BIOMERICA INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/73290/000149315224018697/0001493152-24-018697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/73290/000149315224018697/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018697
- JSON: https://secwatch.observer/filing/0001493152-24-018697.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018697.txt

## Key facts
- Listing & Compliance Notices
  BIOMERICA INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: May 7, 2024, Biomerica, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for the Company’s common stock had been below $1.00 per share for the previous 32 consecutive business days and that the Company is no longer in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market. The Notice indicates the Company will have 180 calenda
  evidence_url: https://www.sec.gov/Archives/edgar/data/73290/000149315224018697/0001493152-24-018697-index.htm
- Material Agreements
  BIOMERICA INC entered into At Market Issuance Sales Agreement with EF Hutton LLC and R.F. Lafferty & Co., Inc. valued at $5,500,000 (effective 2024-05-10).
  - Action: entry
  - Agreement: atm program
  - Counterparty: EF Hutton LLC and R.F. Lafferty & Co., Inc.
  - Value: $5,500,000
  - Effective: 2024-05-10
  source text: On May 10, 2024, Biomerica, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with EF Hutton LLC and R.F. Lafferty & Co., Inc. (each individually, a “Sales Agent” and together, the “Sales Agents”), pursuant to which the Company may offer and sell from time to time up to an aggregate of $5,500,000 of shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/73290/000149315224018697/0001493152-24-018697-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.